U.S. Markets closed

Regeneron Pharmaceuticals, Inc. (REGN)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
455.17-0.53 (-0.12%)
At close: 4:00PM EDT
People also watch
ALXNBIIBCELGVRTXBMRN

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road
Tarrytown, NY 10591
United States
914-847-7000
http://www.regeneron.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees5,505

Key Executives

NameTitlePayExercisedAge
Dr. Leonard S. Schleifer M.D., Ph.D.Co-Founder, Chief Exec. Officer, Pres and Exec. Director3.71M89.94M64
Dr. George D. Yancopoulos M.D., Ph.D.Pres, Chief Scientific Officer and Director3.14M70.18M57
Mr. Robert E. Landry Jr.Chief Financial Officer and Sr. VP of Fin.1.21MN/A53
Dr. Neil Stahl Ph.D.Exec. VP of R&D1.2MN/A60
Mr. Robert J. TerifayExec. VP of Commercial1.07MN/A57
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children’s. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. The company also develops EYLEA, trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma. Regeneron Pharmaceuticals, Inc. has collaboration agreement with Sanofi for the development of antibody-based clinical products comprising Praluent, Sarilumab, Dupixent, REGN2810, REGN3500, and REGN3767; Bayer HealthCare LLC for the development of Nesvacumab/aflibercept, which is used in ophthalmology; and with Teva and Mitsubishi Tanabe Pharma Corporation for developing Fasinumab, an antibody to nerve growth factor, as well as collaboration agreement with Intellia Therapeutics, Inc., to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development. The company was founded in 1988 and is headquartered in Tarrytown, New York.

Corporate Governance

Regeneron Pharmaceuticals, Inc.’s ISS Governance QualityScore as of May 1, 2017 is 10. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 10; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.